Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib with or without Bevacizumab in First-Line Metastatic EGFR-Mutant NSCLC
NCT04181060Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2020
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 10 years. Started Dec 2020; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04181060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181060.